Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ALLEGRA HIVES versus MECLIZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S ALLEGRA HIVES versus MECLIZINE HYDROCHLORIDE.
CHILDREN'S ALLEGRA HIVES vs MECLIZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a selective peripheral H1-receptor antagonist that blocks histamine-mediated effects, reducing pruritus and urticaria.
Meclizine is a histamine H1 receptor antagonist that acts centrally in the vestibular system to suppress nausea and vomiting. It also has anticholinergic and sedative effects.
Fexofenadine 180 mg orally once daily for adults and children 12 years and older.
25-50 mg orally, 3 to 4 times daily for vertigo; 25-50 mg orally 1 hour before travel, may repeat every 24 hours as needed for motion sickness.
None Documented
None Documented
Terminal half-life: 14.4 hours; clinical context: supports twice-daily dosing in chronic urticaria
Terminal elimination half-life: 6 hours (range 5-10 hours). Clinical context: Supports twice-daily dosing; steady-state achieved in approximately 24 hours.
Fecal (80% as unchanged drug); renal (15%, mostly as metabolites; <5% unchanged)
Renal (unchanged and metabolites): 50%; fecal: 40%; biliary: 10%
Category C
Category A/B
Antihistamine
Antihistamine